Translational Application of the Five-Star Matrix for the Structure-Guided Optimization of a Bicyclopiperazine DEL Hit into Bcpz 1.5: A Potent Monoacylglycerol Lipase Inhibitor with Functional Inhibition in Human Brain Homogenate and Efficacy in Neuroinflammatory Models
- 8 October 2026
- journal article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (21) , 25832-25854
Abstract
Monoacylglycerol lipase (MAGL) is a promising therapeutic target for neuroinflammatory conditions. We have previously reported on MAGLi 432, a reversible MAGL inhibitor with activity in mouse models of neuroinflammation. In this full account, we report on the structure-guided optimization of a bicyclopiperazine (Bcpz) DEL hit into potent, selective and brain-penetrant reversible MAGL inhibitor 1.5 (MAGLi 432), guided by the “Five-Star Matrix” translational framework. Compound 1.5 combines excellent MAGL potency (IC50 = 3.2 nM) and selectivity over other serine hydrolases with favorable pharmacokinetic properties, including a 5.7 h half-life after oral administration in male Wistar rats, and CNS drug-like potential. Furthermore, as previously reported, the compound demonstrated robust brain penetration and efficacy in preclinical mouse models of neuroinflammation correlating with inhibition of MAGL activity in mouse and human brain homogenate. This work highlights the power of combining DEL screening and SBDD with the Five-Star Matrix to deliver drug-like candidates for neuroinflammatory disorders.Keywords
This publication has 81 references indexed in Scilit:
- A Highly Selective and Versatile Probe Platform for Visualization of Monoacylglycerol LipaseAngewandte Chemie International Edition, 2025
- Development of a Highly Selective NanoBRET Probe to Assess MAGL Inhibition in Live CellsChemBioChem, 2024
- A Double-Blind, Randomized, Placebo-Controlled Trial of Soluble Epoxide Hydrolase Inhibition in Patients with Aneurysmal Subarachnoid HemorrhageNeurocritical Care, 2021
- European clinical guidelines for Tourette syndrome and other tic disorders: summary statementEuropean Child & Adolescent Psychiatry, 2021
- Monoacylglycerol Lipase Inhibition in Tourette Syndrome: A 12‐Week, Randomized, Controlled StudyMovement Disorders, 2021
- Monoacylglycerol lipase inhibitors: modulators for lipid metabolism in cancer malignancy, neurological and metabolic disordersActa Pharmaceutica Sinica B, 2020
- Monoacylglycerol lipase (MAGL) as a promising therapeutic targetBiochemical Pharmacology, 2018
- Predicting Clearance Mechanism in Drug Discovery: Extended Clearance Classification System (ECCS)Pharmaceutical Research, 2015
- The Role of Monoacylglycerol Lipase (MAGL) in the Cancer ProgressCell Biochemistry and Biophysics, 2014
- Crystal structure of a soluble form of human monoglyceride lipase in complex with an inhibitor at 1.35 Å resolutionProtein Science, 2011